# Matthew D. Galsky

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matthew-d-galsky/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,715 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 81 |
| i10-index | 341 |
| Last Known Institution | Mount Sinai Hospital |
| OpenAlex ID | https://openalex.org/A5018275141 |
| ORCID iD | https://orcid.org/0000-0001-7655-9378 |
| Works | 901 |

## Researcher papers

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [Mount Sinai Hospital](https://scholariq.org/institutions/mount-sinai-hospital-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.